Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Subjects With Renal Impairment”

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04364464
What this trial is testing

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Who this might be right for
Clinical Pharmacology
Bayer 40
Early research (Phase 1)Study completedNCT00715702
What this trial is testing

Safety Study of AZD5672 in Renally Impaired Subjects

Who this might be right for
Renal Impairment
AstraZeneca 40
Large-scale testing (Phase 3)Study completedNCT03644264
What this trial is testing

PA21 Safety and Efficacy in Adult Chinese Subjects

Who this might be right for
Chronic Kidney Disease Requiring Chronic DialysisHyperphosphatemia
Vifor Fresenius Medical Care Renal Pharma 286
Post-approval studies (Phase 4)Ended earlyNCT03226899
What this trial is testing

Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Who this might be right for
GoutChronic Kidney Disease (CKD)
Ironwood Pharmaceuticals, Inc. 242
Early research (Phase 1)Study completedNCT04006093
What this trial is testing

Apixaban in Subjects With Peritoneal Dialysis

Who this might be right for
Chronic Renal InsufficiencyPeritoneal Dialysis
University Hospital, Caen 24
Large-scale testing (Phase 3)Ended earlyNCT01818687
What this trial is testing

Safety and Tolerability Study of MCI-196

Who this might be right for
Chronic Kidney DiseaseNot on DialysisHyperphosphatemia+1 more
Tanabe Pharma Corporation 4
Early research (Phase 1)UnknownNCT05328843
What this trial is testing

Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function

Who this might be right for
Type2Diabetes
PegBio Co., Ltd. 24
Early research (Phase 1)WithdrawnNCT01407900
What this trial is testing

Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction

Who this might be right for
Heart FailureRenal Insufficiency
John A. Schirger
Large-scale testing (Phase 3)Study completedNCT02876835
What this trial is testing

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Who this might be right for
Anaemia
GlaxoSmithKline 3,872
Large-scale testing (Phase 3)Study completedNCT00440557
What this trial is testing

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Who this might be right for
Anemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 375
Early research (Phase 1)Study completedNCT01825889
What this trial is testing

Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Who this might be right for
Cardiovascular Disease
Eli Lilly and Company 20
Large-scale testing (Phase 3)Study completedNCT02065791
What this trial is testing

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Who this might be right for
Diabetes Mellitus, Type 2Diabetic Nephropathy
Janssen Research & Development, LLC 4,401
Early research (Phase 1)Study completedNCT03097016
What this trial is testing

Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Who this might be right for
Renal Insufficiency
Celgene 48
Testing effectiveness (Phase 2)Study completedNCT01843387
What this trial is testing

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Who this might be right for
Diabetic NephropathyType 2 Diabetes
Mesoblast, Ltd. 30
Early research (Phase 1)Study completedNCT00938158
What this trial is testing

The Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Who this might be right for
Diabetes Mellitus, Type 2
GlaxoSmithKline 75
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07323095
What this trial is testing

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Who this might be right for
Chronic Kidney Disease
Atom Therapeutics Co., Ltd 80
Early research (Phase 1)Study completedNCT02833857
What this trial is testing

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Who this might be right for
Chronic Kidney Disease, Secondary Hyperparathyroidism
Amgen 11
Early research (Phase 1)Study completedNCT04476407
What this trial is testing

Pharmacokinetics of Benapenem in Subjects With Renal Impairment

Who this might be right for
Complicated Urinary Tract Infection; Cuti
Sihuan Pharmaceutical Holdings Group Ltd. 18
Early research (Phase 1)Study completedNCT01122667
What this trial is testing

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Who this might be right for
Dyslipidemia
Merck Sharp & Dohme LLC 24
Early research (Phase 1)Study completedNCT02048787
What this trial is testing

Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

Who this might be right for
Renal Impairment
Novartis Pharmaceuticals 19
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation